Fred E Cooperrider

Array ( [id] => 779094 [patent_doc_number] => 06994961 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2006-02-07 [patent_title] => 'Gene expression in ectodermal dysplasia' [patent_app_type] => utility [patent_app_number] => 09/490187 [patent_app_country] => US [patent_app_date] => 2000-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6164 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 240 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/994/06994961.pdf [firstpage_image] =>[orig_patent_app_number] => 09490187 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4357392 [patent_doc_number] => 06255110 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-07-03 [patent_title] => 'Antisense modulation of ARA70 expression' [patent_app_type] => 1 [patent_app_number] => 9/488857 [patent_app_country] => US [patent_app_date] => 2000-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17289 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/255/06255110.pdf [firstpage_image] =>[orig_patent_app_number] => 488857 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4407152 [patent_doc_number] => 06300103 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-10-09 [patent_title] => 'Anti-microbial proteins' [patent_app_type] => 1 [patent_app_number] => 9/488200 [patent_app_country] => US [patent_app_date] => 2000-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 9 [patent_no_of_words] => 4948 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/300/06300103.pdf [firstpage_image] =>[orig_patent_app_number] => 488200 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4182071 [patent_doc_number] => 06159734 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2000-12-12 [patent_title] => 'Antisense modulation of peroxisome proliferator-activated receptor gamma expression' [patent_app_type] => 1 [patent_app_number] => 9/484345 [patent_app_country] => US [patent_app_date] => 2000-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28722 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/159/06159734.pdf [firstpage_image] =>[orig_patent_app_number] => 484345 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4376471 [patent_doc_number] => 06303374 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-10-16 [patent_title] => 'Antisense modulation of caspase 3 expression' [patent_app_type] => 1 [patent_app_number] => 9/484617 [patent_app_country] => US [patent_app_date] => 2000-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34547 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 155 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/303/06303374.pdf [firstpage_image] =>[orig_patent_app_number] => 484617 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1418358 [patent_doc_number] => 06506590 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2003-01-14 [patent_title] => 'Plasmids, their construction and their use in the manufacture of interleukin-4 and interleukin-4 muteins' [patent_app_type] => B1 [patent_app_number] => 09/483419 [patent_app_country] => US [patent_app_date] => 2000-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 3144 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/506/06506590.pdf [firstpage_image] =>[orig_patent_app_number] => 09483419 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4301835 [patent_doc_number] => 06187586 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-02-13 [patent_title] => 'Antisense modulation of AKT-3 expression' [patent_app_type] => 1 [patent_app_number] => 9/474922 [patent_app_country] => US [patent_app_date] => 1999-12-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22792 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/187/06187586.pdf [firstpage_image] =>[orig_patent_app_number] => 474922 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1533710 [patent_doc_number] => 06410689 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-06-25 [patent_title] => 'Caspase recruitment domain polypeptides' [patent_app_type] => B1 [patent_app_number] => 09/470271 [patent_app_country] => US [patent_app_date] => 1999-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 4 [patent_no_of_words] => 25911 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 167 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/410/06410689.pdf [firstpage_image] =>[orig_patent_app_number] => 09470271 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4269802 [patent_doc_number] => 06323003 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-11-27 [patent_title] => 'Compositions and methods for activating genes of interest' [patent_app_type] => 1 [patent_app_number] => 9/446402 [patent_app_country] => US [patent_app_date] => 1999-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 8280 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/323/06323003.pdf [firstpage_image] =>[orig_patent_app_number] => 446402 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1531770 [patent_doc_number] => 06410238 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-06-25 [patent_title] => 'Box-dependent Myc-interacting protein (Bin1) compositions and uses thereof' [patent_app_type] => B1 [patent_app_number] => 09/445247 [patent_app_country] => US [patent_app_date] => 1999-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 21 [patent_no_of_words] => 25821 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/410/06410238.pdf [firstpage_image] =>[orig_patent_app_number] => 09445247 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1544720 [patent_doc_number] => 06444426 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-09-03 [patent_title] => 'Production and use of normalized DNA libraries' [patent_app_type] => B1 [patent_app_number] => 09/437905 [patent_app_country] => US [patent_app_date] => 1999-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 6832 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/444/06444426.pdf [firstpage_image] =>[orig_patent_app_number] => 09437905 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4316204 [patent_doc_number] => 06316698 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-11-13 [patent_title] => 'Plant alpha-glucosidase II homologs' [patent_app_type] => 1 [patent_app_number] => 9/437054 [patent_app_country] => US [patent_app_date] => 1999-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 1 [patent_no_of_words] => 18099 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/316/06316698.pdf [firstpage_image] =>[orig_patent_app_number] => 437054 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6142451 [patent_doc_number] => 20020002278 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-01-03 [patent_title] => 'RANDOM INTRACELLULAR METHOD FOR OBTAINING OPTIMALLY ACTIVE NUCLEIC ACID MOLECULES' [patent_app_type] => new [patent_app_number] => 09/434598 [patent_app_country] => US [patent_app_date] => 1999-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 11571 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0002/20020002278.pdf [firstpage_image] =>[orig_patent_app_number] => 09434598 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1466770 [patent_doc_number] => 06458567 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-10-01 [patent_title] => 'Hepatitis C Virus ribozymes' [patent_app_type] => B1 [patent_app_number] => 09/431419 [patent_app_country] => US [patent_app_date] => 1999-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 35 [patent_no_of_words] => 12311 [patent_no_of_claims] => 78 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/458/06458567.pdf [firstpage_image] =>[orig_patent_app_number] => 09431419 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4419007 [patent_doc_number] => 06177273 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-01-23 [patent_title] => 'Antisense modulation of integrin-linked kinase expression' [patent_app_type] => 1 [patent_app_number] => 9/428219 [patent_app_country] => US [patent_app_date] => 1999-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23227 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/177/06177273.pdf [firstpage_image] =>[orig_patent_app_number] => 428219 [rel_patent_id] =>[rel_patent_doc_number] =>)